2,005 Shares in Natera, Inc. $NTRA Bought by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,005 shares of the medical research company’s stock, valued at approximately $339,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NTRA. Bank of Jackson Hole Trust acquired a new position in shares of Natera in the 1st quarter valued at about $29,000. TCTC Holdings LLC raised its holdings in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after buying an additional 124 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after buying an additional 106 shares in the last quarter. Hilltop National Bank acquired a new position in Natera during the second quarter valued at approximately $33,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new stake in Natera during the second quarter worth approximately $36,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on NTRA. Royal Bank Of Canada set a $268.00 price target on Natera and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $200.00 target price on shares of Natera in a research report on Tuesday, October 14th. Morgan Stanley reiterated an “overweight” rating and set a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Wells Fargo & Company assumed coverage on Natera in a research report on Monday, September 22nd. They set an “equal weight” rating and a $175.00 price target on the stock. Finally, Piper Sandler restated an “overweight” rating and issued a $220.00 price target (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $196.81.

Natera Trading Down 0.9%

NTRA stock opened at $186.88 on Wednesday. The stock’s 50 day simple moving average is $169.37 and its 200 day simple moving average is $159.17. Natera, Inc. has a 12-month low of $117.27 and a 12-month high of $196.63. The firm has a market cap of $25.65 billion, a P/E ratio of -97.84 and a beta of 1.74.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same quarter last year, the company earned ($0.30) EPS. Natera’s revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Rowan E. Chapman sold 2,750 shares of the stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the transaction, the director owned 6,015 shares in the company, valued at $1,004,444.85. This represents a 31.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 14,083 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $160.00, for a total transaction of $2,253,280.00. Following the transaction, the chief executive officer directly owned 154,072 shares in the company, valued at approximately $24,651,520. The trade was a 8.38% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 68,195 shares of company stock worth $10,367,245. 5.63% of the stock is owned by company insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.